PriceTargets.com logo

Trulieve Cannabis - TCNNF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.75
  • Forecasted Upside: 247.51%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.82 As of 12/20/2024 06:55 PM ET
▲ +0.0365 (0.76%)

This chart shows the closing price for TCNNF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Trulieve Cannabis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCNNF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCNNF

Analyst Price Target is $16.75
▲ +247.51% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Trulieve Cannabis in the last 3 months. The average price target is $16.75, with a high forecast of $19.00 and a low forecast of $14.50. The average price target represents a 247.51% upside from the last price of $4.82.

This chart shows the closing price for TCNNF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Trulieve Cannabis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$14.50 ➝ $14.50
5/10/2024Needham & Company LLCBoost TargetBuy ➝ Buy$13.50 ➝ $14.50
5/10/2024Roth MkmBoost TargetBuy ➝ Buy$16.00 ➝ $19.00
3/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$6.50 ➝ $13.50
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$9.00 ➝ $6.50
8/11/2023WedbushLower TargetOutperform ➝ Outperform$8.00 ➝ $6.00
8/10/2023Stifel NicolausBoost TargetC$8.00 ➝ C$9.00
8/10/2023Needham & Company LLCLower TargetBuy ➝ Buy$10.00 ➝ $9.00
7/31/2023Stifel NicolausLower TargetC$20.00 ➝ C$8.00
5/11/2023Stifel NicolausLower TargetC$25.00 ➝ C$20.00
5/11/2023Alliance Global PartnersLower TargetC$24.00 ➝ C$16.00
3/9/2023Needham & Company LLCLower TargetBuy$14.25 ➝ $12.00
3/9/2023Stifel NicolausLower TargetC$34.00 ➝ C$25.00
3/9/2023Craig HallumLower Target$20.00 ➝ $10.00
3/6/2023Cantor FitzgeraldLower TargetOverweight$41.00 ➝ $37.00
2/8/2023Stifel NicolausLower TargetC$36.50 ➝ C$34.00
12/1/2022WedbushInitiated CoverageOutperform$18.00
11/10/2022Canaccord Genuity GroupLower TargetC$54.00 ➝ C$50.00
11/10/2022Cantor FitzgeraldLower TargetOverweight$54.00 ➝ $51.00
8/12/2022Canaccord Genuity GroupLower TargetBuy ➝ BuyC$65.00 ➝ C$57.00
8/11/2022Stifel NicolausLower TargetC$40.00 ➝ C$36.50
8/11/2022Craig HallumLower Target$40.00 ➝ $32.00
8/11/2022CowenLower Target$65.00 ➝ $24.00
8/11/2022Cantor FitzgeraldLower TargetOverweight$57.00 ➝ $54.00
5/12/2022Alliance Global PartnersLower TargetC$60.00 ➝ C$50.00
3/31/2022Canaccord Genuity GroupLower TargetBuy ➝ BuyC$70.00 ➝ C$65.00
3/31/2022Needham & Company LLCLower TargetBuy$50.00 ➝ $47.00
3/30/2022Alliance Global PartnersLower TargetC$76.00 ➝ C$60.00
3/29/2022Cantor FitzgeraldLower TargetOverweight$72.00 ➝ $60.00
2/28/2022Craig HallumLower Target$70.00 ➝ $60.00
2/18/2022Needham & Company LLCLower TargetBuy$54.00 ➝ $50.00
1/7/2022Wolfe ResearchInitiated CoverageOutperform
12/6/2021Cantor FitzgeraldLower TargetOverweight ➝ Overweight$73.00 ➝ $72.00
11/3/2021Cantor FitzgeraldLower TargetOverweight$77.00 ➝ $73.00
11/1/2021Stifel NicolausBoost TargetBuyC$132.00 ➝ C$135.00
10/5/2021Stifel NicolausReiterated RatingBuy
10/4/2021Echelon Wealth PartnersReiterated RatingBuy$75.00
10/4/2021Roth CapitalLower TargetBuy$72.00 ➝ $65.00
10/4/2021Craig HallumLower TargetBuy$80.00 ➝ $70.00
9/22/2021Cantor FitzgeraldBoost TargetOverweight$50.50 ➝ $81.00
8/5/2021Needham & Company LLCBoost TargetBuy$62.25 ➝ $68.25
7/7/2021Jefferies Financial GroupInitiated CoverageBuy$62.00
5/12/2021Stifel NicolausBoost TargetBuy$118.00 ➝ $132.00
5/12/2021Cantor FitzgeraldLower TargetOverweight$76.00 ➝ $71.00
5/6/2021Cantor FitzgeraldLower TargetOverweight$89.00 ➝ $76.00
4/30/2021Cantor FitzgeraldBoost TargetOverweight$83.00 ➝ $89.00
4/15/2021CowenInitiated CoverageOutperform
3/25/2021Stifel NicolausBoost TargetBuy$107.00 ➝ $118.00
3/24/2021Cantor FitzgeraldBoost Target$70.00 ➝ $84.00
3/24/2021Needham & Company LLCBoost TargetBuy$60.50 ➝ $60.75
3/8/2021BTIG ResearchInitiated CoverageBuy
2/25/2021Stifel NicolausBoost TargetBuy$53.00 ➝ $107.00
2/4/2021Roth CapitalInitiated CoverageBuy$60.00
1/26/2021Alliance Global PartnersBoost TargetBuy$66.00
1/19/2021Needham & Company LLCBoost TargetBuy$36.25 ➝ $60.50
11/18/2020Craig HallumBoost TargetBuy$45.00 ➝ $50.00
11/17/2020Alliance Global PartnersReiterated RatingBuy$40.00 ➝ $50.00
11/17/2020Cantor FitzgeraldBoost TargetOverweight$60.00 ➝ $63.00
10/27/2020M PartnersReiterated RatingBuy$31.00
9/25/2020Alliance Global PartnersInitiated CoverageBuy
9/17/2020Cantor FitzgeraldBoost TargetOverweight$59.00 ➝ $60.00
8/13/2020Cantor FitzgeraldReiterated RatingBuy
8/4/2020Needham & Company LLCBoost TargetBuy$18.20 ➝ $29.25
7/22/2020Stifel NicolausInitiated CoverageBuy
6/30/2020Cantor FitzgeraldBoost TargetOverweight$50.00 ➝ $52.00
5/25/2020Echelon Wealth PartnersReiterated RatingBuy$23.00
5/20/2020Needham & Company LLCBoost TargetBuy$17.20 ➝ $18.20
5/13/2020Needham & Company LLCBoost TargetBuy$15.50 ➝ $17.20
4/8/2020Needham & Company LLCBoost TargetBuy$15.25 ➝ $15.50
4/6/2020Cantor FitzgeraldBoost TargetOverweight$30.00 ➝ $32.00
3/23/2020Needham & Company LLCLower TargetBuy$20.00 ➝ $15.25
2/13/2020Cantor FitzgeraldInitiated CoverageUnderweight ➝ Overweight$30.00
1/22/2020Echelon Wealth PartnersReiterated RatingBuy$21.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 5 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Trulieve Cannabis logo
Trulieve Cannabis Corp., together with its subsidiaries, operates as a cannabis retailer. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, creams, balms, salves, lotions, vaporizers, batteries, cartridge, concentrates, topicals, capsules, synringes, tinctures, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It also operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida.
Read More

Today's Range

Now: $4.82
Low: $4.70
High: $5.11

50 Day Range

MA: $8.20
Low: $4.48
High: $13.60

52 Week Range

Now: $4.82
Low: $4.44
High: $14.50

Volume

334,477 shs

Average Volume

519,026 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Trulieve Cannabis?

The following Wall Street sell-side analysts have issued reports on Trulieve Cannabis in the last year: Needham & Company LLC, and Roth Mkm.
View the latest analyst ratings for TCNNF.

What is the current price target for Trulieve Cannabis?

0 Wall Street analysts have set twelve-month price targets for Trulieve Cannabis in the last year. Their average twelve-month price target is $16.75, suggesting a possible upside of 247.5%. Roth Mkm has the highest price target set, predicting TCNNF will reach $19.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $14.50 for Trulieve Cannabis in the next year.
View the latest price targets for TCNNF.

What is the current consensus analyst rating for Trulieve Cannabis?

Trulieve Cannabis currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCNNF will outperform the market and that investors should add to their positions of Trulieve Cannabis.
View the latest ratings for TCNNF.

What other companies compete with Trulieve Cannabis?

Other companies that are similar to Trulieve Cannabis include 180 Life Sciences, 4D pharma, 4Front Ventures, Abattis Bioceuticals and Aeolus Pharmaceuticals. Learn More about companies similar to Trulieve Cannabis.

How do I contact Trulieve Cannabis' investor relations team?

Trulieve Cannabis' physical mailing address is 6749 Ben Bostic Road, Quincy, FL 32351. The company's listed phone number is (850) 480-7955. The official website for Trulieve Cannabis is www.trulieve.com. Learn More about contacing Trulieve Cannabis investor relations.